Salarius Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Decoy Therapeutics

13/05/2022 24:57

* Salarius Pharmaceuticals Inc  SLRX.OQ  reported a
quarterly
adjusted loss of 13 cents​​ per share for the quarter ended in
March. The lone analyst forecast for the quarter was for a loss
of 9 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Salarius Pharmaceuticals Inc shares had fallen by 59.8%
this
quarter and lost 67.7% so far this year.
    * The company reported a quarterly loss of $6.11 million.
    * Wall Street's median 12-month price target for Salarius
Pharmaceuticals Inc is $4.25 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated May 12 at 11:56 p.m.  ​All
figures in US dollars unless otherwise stated